Zhejiang Jiangbei Pharmaceutical Co. Ltd.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of mesalazine enteric-coated tablets (specification: 0.5g, applicant: Zhejiang Jiangbei Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Salfo®, specification: 0.5g, licensee: Dr. Falk Pharma GmbH) after a single oral dose in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of the test formulation of mesalazine enteric-coated tablets (specification: 0.5g) and the reference formulation (trade name: Salfo®, specification: 0.5g) in healthy Chinese adult subjects.

Main study objectives: To study the pharmacokinetics of the test preparation empagliflozin tablets (specification: 10 mg, produced by Zhejiang Jiangbei Pharmaceutical Co., Ltd.) and the reference preparation empagliflozin tablets (Otangjing®, specification: 10 mg, produced by Boehringer Ingelheim Pharma GmbH & Co. KG, licensed by Boehringer Ingelheim International GmbH) in healthy adult subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations after oral administration under fasting conditions. Secondary study objectives: To evaluate the safety of the test preparation and reference preparation of empagliflozin tablets after a single oral administration under fasting conditions in healthy subjects.

Primary objective: To evaluate the bioequivalence of the two preparations in fasting and postprandial states in healthy Chinese subjects, using Ezetimibe Atorvastatin Calcium Tablets (trade name: Atozet, specification: 10mg/20mg) from Organon Healthcare GmbH as the reference preparation and Ezetimibe Atorvastatin Calcium Tablets (II) (specification: each tablet contains 10mg ezetimibe and 20mg atorvastatin calcium (calculated as C33H35FN2O5)) developed by Zhejiang Jiangbei Pharmaceutical Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.